


CLAIMS

We claim:

1. A compound of the general formula



where

m is an integer from 0 to 5;

n is an integer from 0 to 5;


R is C₁ to C₇ alkyl, cycloalkyl, phenyl, hydroxy, alkyl hydroxy, substituted phenyl, or CH₂X¹, where X¹ = H, Cl, Br, I or F;

R₁ is H, C₁ to C₇ alkyl, phenyl, or substituted phenyl;


R₂, R₃, R₄ and R₅ are H or C₁ to C₇ alkyl, and R₁, R₂, R₃, R₄ and R₅ may be the same or different; and

X is a saturated or unsaturated C₁ to C₂ carbon chain.


2. A compound of formula




1 3. A compound of formula




1 4. A compound of formula




1 5. A compound of formula



6. A compound of formula



7. A method of treatment of a condition or disorders related to cannabinoid-regulated systems in a patient in need thereof, comprising the step of administering to said patient a quantity of a compound of generic formula



where

m is an integer from 0 to 5;

n is an integer from 0 to 5;

R is C₁ to C₇ alkyl, cycloalkyl, phenyl, hydroxy, alkyl hydroxy, substituted phenyl, or CH₂X¹, where X¹ = H, Cl, Br, I or F;

R₁ is H, C₁ to C₇ alkyl, phenyl, or substituted phenyl;

R₂, R₃, R₄ and R₅ are H or C₁ to C₇ alkyl, and R₁, R₂, R₃, R₄ and R₅ may be the same or different; and


X is a saturated or unsaturated C₁ to C₂ carbon chain,
in a quantity sufficient to ameliorate symptoms of said condition or disorder.

1 8. The method of claim 7 wherein said condition or disorder is selected from the group
2 consisting of acute and chronic pain, inflammation, loss of appetite, convulsions, multiple
3 sclerosis, nausea and vomiting.

1 9. A compound having a sulfonamide moiety which functions as a silent antagonist of the CB1
2 cannabinoid receptor.

1 10. A method for treating pain in a patient comprising administering to said patient an effective
2 dose of a silent antagonist of a CB1 cannabinoid receptor wherein said silent antagonist includes
3 a sulfonamide moiety.

1 11. The method of claim 10 wherein said silent antagonist has the generic chemical formula



2 where

3 m is an integer from 0 to 5;

4 n is an integer from 0 to 5;


5 R is C_1 to C_7 alkyl, cycloalkyl, phenyl, hydroxy, alkyl hydroxy, substituted phenyl, or
6 CH_2X^1 , where $X^1 = H, Cl, Br, I$ or F ;

7 R_1 is H, C_1 to C_7 alkyl, phenyl, or substituted phenyl;

8 R_2, R_3, R_4 and R_5 are H or C_1 to C_7 alkyl, and R_1, R_2, R_3, R_4 and R_5 may be the same or
9 different; and


10 X is a saturated or unsaturated C_1 to C_2 carbon chain.

12. The method of claim 10 wherein said silent antagonist is



13. A method for treating nausea in a patient comprising administering to said patient an effective dose of a silent antagonist of a CB1 cannabinoid receptor wherein said silent antagonist includes a sulfonamide moiety.

14. The method of claim 12 wherein said silent antagonist has the generic chemical formula



where

m is an integer from 0 to 5;

n is an integer from 0 to 5;


R is C_1 to C_7 alkyl, cycloalkyl, phenyl, hydroxy, alkyl hydroxy, substituted phenyl, or CH_2X^1 , where $\text{X}^1 = \text{H}, \text{Cl}, \text{Br}, \text{I}$ or F ;

R_1 is H, C_1 to C_7 alkyl, phenyl, or substituted phenyl;

$\text{R}_2, \text{R}_3, \text{R}_4$ and R_5 are H or C_1 to C_7 alkyl, and $\text{R}_1, \text{R}_2, \text{R}_3, \text{R}_4$ and R_5 may be the same or different; and

X is a saturated or unsaturated C_1 to C_2 carbon chain.

1 15. The method of claim 13, wherein said silent antagonist is



1 16. A method of blocking the effects of a CB1 cannabinoid receptor agonist in a patient,
2 comprising the step of administering to said patient an effective dose of a silent antagonist of the
3 CB1 cannabinoid receptor wherein said silent antagonist includes a sulfonamide moiety.